Logo

Dominari Holdings Inc.

DOMH

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and a… read more

Healthcare

Biotechnology

43 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.82

Price

-0.51%

-$0.03

Market Cap

$89.153m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$24.891m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$41.750m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$301,508.10

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$42.428m

$52.335m

Assets

$9.907m

Liabilities

$2.917m

Debt
Debt to Assets

5.6%

-0.1x

Debt to EBITDA
Free Cash Flow

-$5.289m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases